David Ehmann, VP Biology
Professional Overview
David Ehmann is an experienced biopharmaceutical executive with a strong track record of driving innovation and delivering impactful results. As the Vice President of Biology at Pretzel Therapeutics, he oversees the company's research and development efforts, applying his deep expertise in translational biology to advance novel therapeutic candidates.
Experience Summary
Current Role
As the VP of Biology at Pretzel Therapeutics, David is responsible for leading the company's research and development strategy, managing cross-functional teams, and ensuring the successful translation of promising biological concepts into viable drug candidates. Under his leadership, the biology team has made significant strides in optimizing lead compounds and progressing multiple programs through preclinical development.
Career Progression
Prior to joining Pretzel Therapeutics, David held various leadership roles within the biopharmaceutical industry. As the Director of Biology at Takeda, he directed a team of scientists in the discovery and development of new therapeutic approaches, contributing to the advancement of several clinical-stage assets. Earlier in his career, David served as an Associate Director at Shire, where he played a key role in the progression of rare disease programs, and as a Principal Scientist and Team Leader at AstraZeneca, where he spearheaded the development of innovative small molecule and biologics platforms.
Academic Background
David holds a Ph.D. in Molecular Biology from the University of California, San Diego, where his research focused on the elucidation of novel signaling pathways and their implications for targeted therapeutic interventions. He has authored numerous peer-reviewed publications and holds several patents related to his work.
Areas of Expertise
- Translational biology and drug discovery
- Therapeutic target identification and validation
- Preclinical development of small molecules and biologics
- Cross-functional team leadership and project management
- Strategic planning and portfolio optimization
Professional Impact
Throughout his career, David has made significant contributions to the biopharmaceutical industry. His work has led to the advancement of multiple drug candidates, including the successful initiation of clinical trials for a novel rare disease therapy during his tenure at Shire. David's expertise in translational biology and his ability to drive innovation have been instrumental in the development of next-generation therapeutics.
Conclusion
With his extensive experience, proven leadership skills, and deep understanding of the biopharmaceutical landscape, David Ehmann is poised to continue driving transformative change as the VP of Biology at Pretzel Therapeutics. His dedication to advancing the field of translational biology and his commitment to developing innovative therapies make him a valuable asset to the company and the industry as a whole.
